1. True or False: Risk of death within one day from hyperkalemia is highest in people with kidney disease.

2. There is a reduced risk of hyperkalemia in patients treated with ARB medications versus ACE inhibitors in which group of patients?

3. Choices for chronic management of hyperkalemia includes all of the following, except:

4. All of the statements about sodium polystyrene sulfonate are true, except:

5. A 71-year-old male patient with HFrEF, NYHA functional class II symptoms, and dyslipidemia, presents to you for routine follow-up. He is on enalapril 10 mg twice daily, spironolactone 25 mg once daily, carvedilol 25 mg once daily, furosemide 40 mg once daily, and rosuvastatin 20 mg once daily. He goes for a 30 minute walk every morning without chest pain but has some shortness of breath. However, these symptoms are not new and have not gotten worse since his last visit ~3 months ago.

You draw routine blood tests. His serum K+ comes back at 5.6 mEq/L, up from 4.8 mEq/L at last visit. The patient’s high potassium is related most likely to:

« Return to Activity